In late April 2026 the Drug Enforcement Administration moved marijuana from Schedule I to Schedule III, a change that acknowledges accepted medical use while still classifying the plant as having a low potential for dependence. The shift was heralded as a milestone for the nascent cannabis industry, but the practical effects have been modest so far. For companies that focus on the medical side of the business, the rescheduling removes a major tax hurdle, yet the benefit is limited to those operating within the narrowly defined medical framework.
Image source: Getty Images.
Medical relief
The DEA’s rescheduling applies only to marijuana intended for medical use. Recreational cannabis remains listed under Schedule I, which means businesses that sell adult‑use products continue to face the same federal restrictions as before. For medical operators, the most immediate impact is the removal of Internal Revenue Service Section 280E limitations. Under 280E, businesses trafficking in a Schedule I substance may deduct only the cost of goods sold; all other ordinary business expenses—such as marketing, rent, salaries, and insurance—are disallowed. By moving to Schedule III, medical cannabis sellers can now deduct those standard expenses, which can improve profitability even if the change does not generate a windfall.
However, the relief is not universal. Health Canada restricts export permits for cannabis to specific medical or research purposes, creating a bottleneck for Canadian firms hoping to ship medical products into the United States. Consequently, even though the U.S. tax environment has become more favorable for medical cannabis, Canadian producers still lack a straightforward legal channel to serve the U.S. medical market.
Canopy Growth illustrates this dynamic. The company maintains a presence in the United States through an affiliate, Canopy USA, in which it holds a non‑controlling stake. This structure lets Canopy retain exposure to American assets—including medical marijuana operations—while preventing the parent from consolidating Canopy USA’s financial results into its own statements. Because of the non‑controlling interest, the exact volume of medical cannabis sold by the U.S. affiliate is not publicly disclosed, and without further legislative change the arrangement is unlikely to shift.
Key Data Points
Canopy Growth’s recent trading performance underscores the challenges it faces. The stock closed at $1.08, down 0.92 % on the day, with a market capitalization of roughly $460 million. Over the past year the share price has ranged from $0.84 to $2.38, and average daily volume is about 9.9 million shares, compared with 27.5 thousand on the most recent session. Gross margin sits at 18.25 %, reflecting ongoing pressure on profitability despite cost‑cutting initiatives and a series of acquisitions that have yet to translate into sustained net income.
This company needs more than a legal shift
The DEA’s move will only materially affect Canopy Growth if it ever obtains a controlling interest in Canopy USA, allowing the affiliate’s results to be folded into the parent’s financials. Until that occurs, the tax advantage provided by Schedule III remains largely out of reach for the Canadian firm’s consolidated earnings. Moreover, the U.S. cannabis market is already crowded with multi‑state operators and vertically integrated players, making it difficult for any single entrant—especially one whose U.S. exposure is indirect—to capture a dominant share.
Given Canopy Growth’s historical pattern of net losses, negative free cash flow, and frequent secondary share offerings that have diluted early investors, the recent rescheduling alone is unlikely to serve as a catalyst for a turnaround. Investors should view the change as a modest step forward for the medical cannabis segment rather than a transformative event for the company’s overall prospects.
